- Home
- INZY vs CIO Comparison
INZY vs CIO Comparison
Compare INZY & CIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- CIO
- Stock Information
- Founded
- INZY 2015
- CIO 2013
- Country
- INZY United States
- CIO Canada
- Employees
- INZY N/A
- CIO N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- CIO Real Estate Investment Trusts
- Sector
- INZY Health Care
- CIO Real Estate
- Exchange
- INZY Nasdaq
- CIO Nasdaq
- Market Cap
- INZY 188.2M
- CIO 202.0M
- IPO Year
- INZY 2020
- CIO 2014
- Fundamental
- Price
- INZY $1.25
- CIO $4.92
- Analyst Decision
- INZY Strong Buy
- CIO
- Analyst Count
- INZY 8
- CIO 0
- Target Price
- INZY $17.75
- CIO N/A
- AVG Volume (30 Days)
- INZY 677.6K
- CIO 130.5K
- Earning Date
- INZY 03-11-2025
- CIO 02-20-2025
- Dividend Yield
- INZY N/A
- CIO 8.13%
- EPS Growth
- INZY N/A
- CIO N/A
- EPS
- INZY N/A
- CIO N/A
- Revenue
- INZY N/A
- CIO $171,126,000.00
- Revenue This Year
- INZY N/A
- CIO N/A
- Revenue Next Year
- INZY N/A
- CIO $0.20
- P/E Ratio
- INZY N/A
- CIO N/A
- Revenue Growth
- INZY N/A
- CIO N/A
- 52 Week Low
- INZY $1.24
- CIO $4.02
- 52 Week High
- INZY $7.80
- CIO $6.50
- Technical
- Relative Strength Index (RSI)
- INZY 31.42
- CIO 39.92
- Support Level
- INZY $1.24
- CIO $4.84
- Resistance Level
- INZY $1.43
- CIO $5.31
- Average True Range (ATR)
- INZY 0.10
- CIO 0.16
- MACD
- INZY 0.04
- CIO -0.00
- Stochastic Oscillator
- INZY 3.12
- CIO 17.02
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About CIO City Office REIT Inc.
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. The company owns office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.